SS
SYRS

Steve Schonfeld’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Steve Schonfeld’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,011
Closed -$28K – 3220
2022
Q2 		$28K Buy
3,011
+1,501
+99% +$14K ﹤0.01% 2280
2022
Q1 		$18K Buy
+1,510
New +$27K ﹤0.01% 2400
2021
Q1 		– Sell
-1,230
Closed -$134K – 2179
2020
Q4 		$134K Buy
+1,230
New +$112K ﹤0.01% 1410

Other funds holding SYRS

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Steve Schonfeld's SYRS Position: Q3 2022 in Review

Steve Schonfeld sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2022, closing a stake of 3,011 shares — an estimated $28K sold.

Steve Schonfeld first reported a position in SYRS in Q4 2020 and held it in 3 quarters. The position peaked at $134K in Q4 2020. 53 funds tracked by Wall St. Rank hold SYRS as of Q3 2022.

  • Steve Schonfeld reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Steve Schonfeld sold 3,011 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $28K.
  • Steve Schonfeld first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Steve Schonfeld's Syros Pharmaceuticals, Inc. Common Stock position peaked at $134K in Q4 2020.
  • 53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.